Former Siemens exec buys stake in Deerfield Imaging; Transcend settles Glaukos patent dispute;

@FierceMedDev: Smith & Nephew to buy robotic surgical partner Blue Belt for $275M. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. Article | Follow @VarunSaxena2

@EmilyWFierce: It seemed like things couldn't get much worse for Theranos. And then, they did. More | Follow @EmilyWFierce

> Dr. Gregory Sorensen, the former president and CEO of Siemens Healthcare North America, will take a minority interest in Deerfield Imaging and become its executive chairman. The company was created in August with the acquisition of Imris image-guided therapy assets out of bankruptcy. More

> Glaukos ($GKOS) has settled with Transcend Medical over patent infringement allegations concerning Transcend's CyPass Micro-Stent devices, appliers and delivery systems, which is not FDA approved. Transcend has agreed to make payments to equal to Glaukos of 1% of any future net sales of CyPass devices up to $6 million in total until April 2022. More

> Medtronic ($MDT) will be able to appeal a decision against it in a patent discute with Florida licensor Atlas IP. Story

Biotech News

@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Something tells me that the Pfizer/Allergan merger will inspire Ian Read to name the new company... Pfizer. | Follow @JohnCFierce

@DamianFierce: "I hope Bill Ackman has done more research on Valeant than he did on Herbalife, Target, Borders and JC Penny." Statement | Follow @DamianFierce

> AstraZeneca's olaparib looks promising among a targeted set of prostate cancer patients. More

> With a new FDA nod, Novartis enters a crowded COPD field. Story

> Sanofi dumps a $663M MS deal with India's Glenmark. Article

> José Almeida, former Covidien CEO, to head Baxter. Chutes and Ladders

Pharma News

@FiercePharma: Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott. Report | Follow @FiercePharma

@EricPFierce: Will Sanofi problems with auto injectors be its auto ejector from the epinephrine market? More | Follow @EricPFierce

@CarlyHFierce: "Pfallergan" - definitely the worst portmanteau I've ever seen for anything, ever. | Follow @CarlyHFierce

> Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott. Report

> Patent challenger Bass wins IP reviews for Celgene, Shire meds. Article

> Mylan beats Street's estimates with Q3 earnings and beats Perrigo in effort to derail tender. Item

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.